Literature DB >> 16960142

COX-2 in inflammation and resolution.

Ravindra Rajakariar1, Muhammad M Yaqoob, Derek W Gilroy.   

Abstract

Aspirin and the other NSAIDs have popularized the notion of inhibiting prostaglandins as a common anti-inflammatory strategy based on the erroneous premise that all eicosanoids are, within the context of inflammation, generally detrimental. However, our fascination with aspirin and the emergence of COX-2 has shown a more affable side to lipid mediators based on our increasing interest in the endogenous control of acute inflammation and in factors that mediate its resolution. Epilipoxins, for instance, are produced from aspirin's acetylation of COX-2 and together with Resolvins and COX-2-derived prostaglandins of the D(2) and J(2) series represent an increasingly important family of immunoregulatory lipid mediators with strong implications for disease control and drug discovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960142     DOI: 10.1124/mi.6.4.6

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  41 in total

1.  Bidirectional crosstalk via IL-6, PGE2 and PGD2 between murine myofibroblasts and alternatively activated macrophages enhances anti-inflammatory phenotype in both cells.

Authors:  Maria R Fernando; Mark A Giembycz; Derek M McKay
Journal:  Br J Pharmacol       Date:  2016-02-08       Impact factor: 8.739

2.  Cyclooxygenase-2 enhances antimicrobial peptide expression and killing of Staphylococcus aureus.

Authors:  Jamie J Bernard; Richard L Gallo
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

Review 3.  Anti-inflammatory and proresolving lipid mediators.

Authors:  Charles N Serhan; Stephanie Yacoubian; Rong Yang
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

4.  Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells.

Authors:  Quein Ahn; Soo-Jin Jeong; Hyo-Jung Lee; Hee-Young Kwon; Ihn Han; Hyun Seok Kim; Hyo-Jeong Lee; Eun-Ok Lee; Kwang Seok Ahn; Min-Hyung Jung; Shudong Zhu; Chang-Yan Chen; Sung-Hoon Kim
Journal:  Cancer Lett       Date:  2010-07-31       Impact factor: 8.679

5.  NF-κB-dependent IL-8 induction by prostaglandin E(2) receptors EP(1) and EP(4).

Authors:  F Neuschäfer-Rube; A Pathe-Neuschäfer-Rube; S Hippenstiel; M Kracht; G P Püschel
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

6.  Inhibitory effect of Zizania latifolia chloroform fraction on allergy-related mediator production in RBL-2H3 cells.

Authors:  Eun-Jung Lee; Mi-Hee Yu; Coralia V Garcia; Kwang-Hwan Jhee; Seun-Ah Yang
Journal:  Food Sci Biotechnol       Date:  2017-04-30       Impact factor: 2.391

7.  MSK1 and MSK2 inhibit lipopolysaccharide-induced prostaglandin production via an interleukin-10 feedback loop.

Authors:  Kirsty F MacKenzie; Mirjam W M Van Den Bosch; Shaista Naqvi; Suzanne E Elcombe; Victoria A McGuire; Alastair D Reith; Perry J Blackshear; Jonathan L E Dean; J Simon C Arthur
Journal:  Mol Cell Biol       Date:  2013-02-04       Impact factor: 4.272

8.  Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection.

Authors:  Matthew P Bernard; Simona Bancos; Timothy J Chapman; Elizabeth P Ryan; John J Treanor; Robert C Rose; David J Topham; Richard P Phipps
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

9.  Plasticity of leukocytic exudates in resolving acute inflammation is regulated by MicroRNA and proresolving mediators.

Authors:  Yongsheng Li; Jesmond Dalli; Nan Chiang; Rebecca M Baron; Carolina Quintana; Charles N Serhan
Journal:  Immunity       Date:  2013-11-14       Impact factor: 31.745

10.  Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery.

Authors:  Chen-Xin Dai; Qiang Gao; Shuang-Jian Qiu; Min-Jie Ju; Ming-Yan Cai; Yong-Feng Xu; Jian Zhou; Bo-Heng Zhang; Jia Fan
Journal:  BMC Cancer       Date:  2009-12-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.